ClinicalTrials.gg
CompletedNCT02045849Updated Jul 13, 2017

Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

A Phase 1 interventional study of GSK2140944 capsule and GSK2140944 tablet in Infections, Bacterial, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-13.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing gepotidacin in Bacterial Infections — 1 open to participants now, 1 under way, none of them phase 3. gepotidacin · Bacterial Infections.

Enrollment
5th of 11
46 · median 34
Started
2014
with 1 other
Phase 1
9 of 11
1 open now
Registered
2nd of 11
by date
Lead sponsor
10 of 11
GlaxoSmithKline

Among the 11 studies testing gepotidacin in Bacterial Infections, this one is the 5th largest by enrollment, is one of 2 that started in 2014, is one of 9 in phase 1, and was the 2nd registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

1 of the 11 studies testing gepotidacin in Bacterial Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About gepotidacin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing gepotidacin in Bacterial Infections, or all of them as a file.
02

Study summary

This study will be conducted in three parts (Part 1, Part 2 and Part 3). Part 1 of this study will evaluate the relative bioavailability of a single dose of GSK2140944 tablet formulation compared to the reference capsule formulation under fasted conditions. The effect of food on the pharmacokinetics (PK) of a single dose of the tablet formulation will also be assessed. Part 2 will evaluate the effect of repeat doses of itraconazole on the pharmacokinetics of GSK2140944 following a single dose. A decision will be made whether to use the current capsule formulation or the new tablet formulation in Part 2 based upon the safety and PK data obtained from Part 1. Part 3 is conditionally based upon progression of the tablet formulation from Part 1 and will evaluate the effect of food on the safety, tolerability, and pharmacokinetics of the tablet formulation following multiple doses in elderly healthy subjects.

03

Conditions studied

  • Infections, Bacterial

Browse trials for

Keywords

  • pharmacokinetics
  • GSK2140944
  • tolerability
  • drug interaction
  • safety
  • itraconazole
  • elderly healthy subjects
  • food effect
  • relative bioavailability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator feels and documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Part 1 and 2: Male or female between 18 and 64 years of age inclusive, at the time of signing the . Part 3: Male or female subjects at least 65 years of age or older at the time of signing the informed consent.
  • A female subject is eligible to participate if she is of: non- defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or defined as 12 months of spontaneous amenorrhea. To confirm post-menopausal status, a blood sample for simultaneous follicle stimulating hormone (FSH) >40 milli-International Units (MIU)/milliliter (mL) and estradiol \<40 picograms (pg)/mL (\<147 picomoles [pmol]/liter [L]) is confirmatory. Male subjects with female partners of child-bearing potential must agree to use one of the methods. This criterion must be followed from the time of the first dose of study medication until the final follow-up visit.
  • Body weight >=50 kilograms (kg) and (BMI) within the range 19 - 31 kg/meter square (m\^2) (inclusive).
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • Alanine amino transferase (), alkaline phosphatase and \<=1.5xUpper Limit of Normal () (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).

Exclusion criteria

Exclusion Criteria:

Criteria Based Upon Medical Histories

  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Any central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of such conditions that, in the opinion of the investigator may place the subject at an unacceptable risk as a participant in this trial or may interfere with the absorption, distribution, metabolism or excretion of drugs.
  • History of photosensitivity to quinolones.
  • Use of systemic antibiotic within 30 days of screening
  • Previous exposure to GSK2140944
  • Confirmed history of C-difficile diarrhea.
  • History of tendon rupture.
  • History of drug abuse within 6 months of the study.
  • History of smoking or use of nicotine containing products within 3 months of screening, or a positive urine cotinine indicative of smoking at screening.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 grams of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia (if the clinical research unit uses heparin to maintain intravenous cannula patency).

Criteria Based Upon Diagnostic Assessments

  • A positive pre-study surface antigen or positive antibody result within 3 months of screening or positive (HIV) antibody.
  • A screening or Day -1 urinalysis positive for protein or glucose (greater than 1+ findings of protein or glucose).
  • A serum creatinine value that is increased by more than 0.2 milligram (mg)/deciliter (dL) (or 15.25 micromoles/L) between screening and Day -1.
  • For Part 3 Only: \<2000 cells/microliter (a single repeat is allowed for eligibility determination).
  • A positive urine test for drugs of abuse or alcohol (or alcohol breath test) at screening or at Day -1.
  • Exclusion criteria for screening and baseline (a single repeat is allowed for eligibility determination) as follows: Heart rate: \<40 and >100 beats per minute (bpm) for males and \<50 and >100 bpm for females; PR Interval: \<120 and >220 milliseconds (msec); QRS duration: \<70 and >100 msec; duration corrected for heart rate by Bazett's formula (QTcB) or QT duration corrected for heart rate by Fridericia's formula (QTcF) interval>450 msec. Evidence of previous myocardial infarction (does not include ST segment changes associated with repolarization). Any conduction abnormality (including but not specific to left or right complete bundle branch block, atrioventricular (AV) block [2nd degree or higher], Wolf Parkinson White [WPW] syndrome), sinus pauses> 3 seconds, non-sustained or sustained ventricular tachycardia (>=3 consecutive ventricular ectopic beats) or any significant arrhythmia which, in the opinion of the principal investigator and GSK medical monitor, will interfere with the safety of the individual subject.

Other Criteria

  • Donation of blood in excess of 500 mL within 12 weeks prior to dosing or participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Unwillingness to commit to avoid excessive exposure to sunlight (or exposure to a tanning bed) which would cause a sunburn reaction from first dose up to and including the follow-up visit.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Part 1

    Subjects will receive either GSK2140944 1500 mg (500 mg x 3) capsules under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fed conditions as per the randomization schedule in each of the three periods with a washout period of at least 3 days between the doses. There will also be a follow-up visit within 5-7 days after the last dose of study drug.

    Drug: GSK2140944 capsule · Drug: GSK2140944 tablet

  • Experimental
    Part 2

    Subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) on Day 1 followed by a repeat dose of Itraconazole 200 mg once daily for 6 days from Day 4 to Day 9. On Day 7, subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) one hour after the dose of Itraconazole. There will also be a follow-up visit within 5-7 days after the last dose of study drug.

    Drug: GSK2140944 capsule · Drug: GSK2140944 tablet · Drug: Itraconazole capsule

  • Experimental
    Part 3

    Subjects in Group 1 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fasting and fed conditions in Period I and Period II, respectively. Subjects in Group 2 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fed and fasting conditions in Period I and Period II, respectively. There will be a washout of at least 7 days between the periods. Subjects will have a follow up visit 5-7 days after the last dose of study drug in both the groups.

    Drug: GSK2140944 tablet

Interventions

  • Immediate release capsule containing GSK2140944 and inactive formulation excipients with a unit dose strength of 500 mg

  • Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg

  • Capsule containing Itraconazole with a unit dose strength of 100 mg

06

What researchers measure

Primary outcomes

  1. Part 1: Composite of PK parameters following GSK2140944 administration in fasted and fed state

    PK parameters will include area under the concentration-time curve (AUC) from time zero (pre-dose) extrapolated to infinite time AUC(0-infinity), AUC from time zero to last quantifiable concentration AUC(0-t), relative bioavailability of drug (Frel), maximum observed concentration (Cmax), time of occurrence of Cmax (tmax), lag time before observation of drug concentration (tlag) and terminal phase half-life (t1/2) in the fasted state; AUC(0-infinity), AUC(0-t), tmax, tlag and Cmax after moderate fat meal.

    Time frame: Day 1 (Pre-dose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, and at 48h)

  2. Part 2: Composite of PK parameters of GSK2140944 following repeat oral dosing of itraconazole

    PK parameters will include AUC(0-infinity), AUC(0-t), tmax, tlag and Cmax of GSK2140944.

    Time frame: Day 1 and Day 7 (Predose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, and 48h post dose and also at 60h and 72h post dose on Day 7

  3. Part 3: Safety and tolerability of GSK2140944 as assessed by adverse events (AEs)

    Time frame: Approximately 8 weeks

  4. Part 3: Safety and tolerability of GSK2140944 as assessed by review of concomitant medications

    Time frame: Approximately 8 weeks

  5. Part 3: Safety and tolerability of GSK2140944 by laboratory assessments

    Laboratory assessments will include hematology, clinical chemistry, urinalysis parameters

    Time frame: Approximately 8 weeks

  6. Part 3: Safety and tolerability of GSK2140944 as assessed by 12-lead electrocardiograms (ECGs)

    All 12-lead ECGs will be obtained after the subject has rested in a supine position for at least 10 minutes

    Time frame: Approximately 8 weeks

  7. Part 3: Safety and tolerability of GSK2140944 as assessed by vital signs

    Vital signs will be measured for subjects in supine position and will include systolic and diastolic blood pressure, pulse rate and temperature

    Time frame: Approximately 8 weeks

Secondary outcomes

  1. Part 1: Safety and tolerability of GSK2140944 as assessed by AEs

    Time frame: Approximately 7 weeks

  2. Part 1: Safety and tolerability of GSK2140944 as assessed by review of concomitant medications

    Time frame: Approximately 7 weeks

  3. Part 1: Safety and tolerability of GSK2140944 by laboratory assessments

    Laboratory assessments will include hematology, clinical chemistry, urinalysis parameters

    Time frame: Approximately 7 weeks

  4. Part 1: Safety and tolerability of GSK2140944 as assessed by 12-lead ECGs

    All 12-lead ECGs will be obtained after the subject has rested in a supine position for at least 10 minutes

    Time frame: Approximately 7 weeks

  5. Part 1: Safety and tolerability of GSK2140944 as assessed by vital signs

    Vital signs will be measured for subjects in supine position and will include systolic and diastolic blood pressure, pulse rate and temperature

    Time frame: Approximately 7 weeks

  6. Part 2: Safety and tolerability of GSK2140944 as assessed by AEs

    Time frame: Approximately 6 weeks

  7. Part 2: Safety and tolerability of GSK2140944 by laboratory assessments

    Laboratory assessments will include hematology, clinical chemistry, urinalysis parameters

    Time frame: Approximately 6 weeks

  8. Part 2: Safety and tolerability of GSK2140944 as assessed by 12-lead ECGs

    All 12-lead ECGs will be obtained after the subject has rested in a supine position for at least 10 minutes

    Time frame: Approximately 6 weeks

  9. Part 2: Safety and tolerability of GSK2140944 as assessed by vital signs

    Vital signs will be measured for subjects in supine position and will include systolic and diastolic blood pressure, pulse rate and temperature

    Time frame: Approximately 6 weeks

  10. Part 3: Composite of PK parameters of GSK2140944 following repeat oral dosing of GSK2140944

    PK parameters will include AUC over the dosing interval (0-tau), tmax, tlag, t1/2, pre-dose (trough) concentration at the end of the dosing interval (Ctau) and Cmax of GSK2140944

    Time frame: Day 3 and Day 4 (Pre-dose), Day 5 (Predose, 0.25h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, and at 48h)

07

Study locations

1 site
  • GSK Investigational Site
    Overland Park, Kansas 66211, United States
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Aug 2014, 6 months.

Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 6 months is below that.

Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2014
First posted
Jan 27, 2014
StartActual
Jan 28, 2014
Primary completionActual
Aug 21, 2014
CompletionActual
Aug 21, 2014
Last update
Jul 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02045849
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 27, 2014
Start date
Jan 28, 2014
Primary completion
Aug 21, 2014
Completion
Aug 21, 2014
Last update
Jul 13, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gepotidacin

Start the discussion